Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 21;121(12):2285-8.
doi: 10.1182/blood-2013-01-475855. Epub 2013 Jan 22.

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

Cassandra J Vandenberg  1 , Suzanne Cory
Affiliations

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

Cassandra J Vandenberg et al. Blood. .

Abstract

BH3-only proteins trigger the stress apoptosis pathway and chemical mimetics have great potential for cancer therapy. BH3-only proteins inhibit antiapoptotic members of the Bcl-2 family. Promising BH3 mimetic ABT-737 and the related orally available compound ABT-263 (navitoclax) bind avidly to antiapoptotic Bcl-2, Bcl-xL, and Bcl-w. However, their interaction with Bcl-xL provokes thrombocytopenia, which has proven to be the dose-limiting toxicity. We have tested the efficacy of ABT-199, a new Bcl-2-specific BH3 mimetic, against aggressive progenitor cell lymphomas derived from bitransgenic myc/bcl-2 mice. As a single agent, ABT-199 was as effective as ABT-737 in prolonging survival of immunocompetent tumor-bearing mice without causing thrombocytopenia. Both drugs acted rapidly but, contrary to prevailing models, their apoptotic activity did not rely upon the BH3-only protein Bim. When ABT-737 was combined with the proteosome inhibitor bortezomib or CDK inhibitor purvalanol, many treated animals achieved long-term remission.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of responsiveness to ABT-737 and ABT-199. (A-B) WBC counts, (C-D) platelet counts, and (E-F) Kaplan-Meier survival curves of mice transplanted with 4 bim+/+ (nos. 9, 12, 16, and 47) and 3 bim−/− (nos. 58, 96, and 324) myc/bcl-2 lymphomas and treated with ABT-737, ABT-199, or the respective vehicles (3 mice per treatment arm for each independent tumor). Blood analyses were performed at 0 hours, 3 hours, and 6 days after starting treatment (day 11 after transplantation), using an ADVIA 2120 hematology analyzer (Siemens Australia New Zealand, VIC, Australia). Bars represent mean + SEM; significant changes observed at 3 hours are indicated: *P < .05, **P < .01, ***P < .001, Student t test. The x-axis in panels E and F indicates days elapsed since start of treatment; the bar indicates the duration of treatment (10 days). Significance for Kaplan-Meier survival curves was determined using the log-rank (Mantel-Cox) test. The median survival of bim+/+ lymphomas treated with ABT-737 was 21.5 days vs 14 days for vehicle (P = .0088), and 23.5 days with ABT-199 vs 13 days for vehicle (P = .0003). The median survival of bim−/− lymphomas treated with ABT-737 was 20.5 days vs 14 days for vehicle (P < .0001), and 19.5 days with ABT-199 vs 13 days for vehicle (P < .0001). One bim−/− lymphoma (no. 324) rebounded early following treatment; unusually, it comprised 50% progenitor (B220+CD4+) and 50% B-lymphoid (B220+CD4−) cells, the latter having higher levels of Mcl-1 (see supplemental Figure 1A), which would confer greater resistance.
Figure 2
Figure 2
Combination therapy with ABT-737 extends survival. Safe regimens were established from previously published data,, and our own dose-finding studies (data not shown). Nonirradiated C57BL/6 recipients were transplanted with 3 independent bim+/+ myc/bcl-2 lymphomas (nos. 9, 12, 16) (3 × 106 tumor cells per mouse) 4 days prior to commencement of treatment. ABT-737 was administered intraperitoneally at 75 mg/kg per day for 10 days (bar), starting on day 1; cyclophosphamide (CTX; 50 mg/kg) intraperitoneally on days 3, 8; bortezomib (0.5 mg/kg) intraperitoneally on days 1, 3, 5, 8, 10; purvalanol A (20 mg/kg) intraperitoneally on days 1, 3, 5, 8, 10, alone or in combination with ABT-737, with at least 6 mice per indicated treatment arm (supplemental Tables 1-2). With tumor 16, all mice treated with ABT-737 alone remained healthy until the experiment was terminated at day 150 (supplemental Table 2 and data not shown; controls treated with vehicle were all dead by day 35).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667–3683. - PMC - PubMed
    1. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–681. - PubMed
    1. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–3428. - PubMed
    1. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389–399. - PMC - PubMed
    1. Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375–388. - PubMed

Publication types

MeSH terms